B+
Bull case
25%
Probability
Target price
$2.72
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
BDTX
Black Diamond TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$2.22
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$1.41
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-17
Recent news sentiment (30D)
+60.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+73.7
Score
AI commentary
The latest company update was clinically constructive, while the stored Associated Press earnings snapshot reported a $0.17 per-share loss versus a $0.18 estimate [#PR-EARNINGS-2026-08-05]. The stock remains a low-coverage, event-driven biotech situation; analyst revisions, options data, short interest, employee sentiment, and social coverage are unavailable, so confidence is limited.
RankAlpha Sentiment Codex - 2026-08-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventQ4 2026 NSCLC update and FDA pivotal-path feedbackHigh impact
Black Diamond expects to provide a Q4 2026 update on the silevertinib Phase 2 frontline non-classical EGFR-mutant NSCLC trial and FDA feedback on a potential pivotal development path. Reported Phase 2 metrics included 60% ORR, 86% CNS ORR, 91% DCR, and preliminary median PFS of 15.2 months [#SEC-8K-2026-08-05].
2026-12-31catalystGBM randomized Phase 2 advancementHigh impact
The silevertinib-plus-temozolomide Phase 2 study in newly diagnosed EGFRvIII-positive glioblastoma is enrolling its safety lead-in, with the randomized portion expected to begin in Q4 2026 [#SEC-8K-2026-08-05].
2028-06-30catalystCash runway reduces near-term financing pressureMedium impact
Cash, cash equivalents, and investments were $110.5 million as of June 30, 2026, and the company expects funding to support operations into the second half of 2028 [#SEC-SEC-8K-2026-08-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-17 • Updated nightlySource: Internal modelMethodology